More like this
BGF MDI 320/14.4/9.6 μG's Phase 3 Trial in COPD Reads Out
ESTIMATED50% CONFIDENCEin 1.2 yearsClinicalTrials.gov[1] lists 2027-12-03 as the estimated primary completion date; a sponsor's estimate, and trials of this size routinely slip.AstraZeneca's phase 3 trial of BGF MDI 320/14.4/9.6 μG in copd reaches primary completion, the point at which the last participant's primary outcome is measured. The trial enrolled 5,000 participants. This study will evaluate the effect of triple ICS/LAMA/LABA therapy with BGF MDI 320/14.4/9.6 μg on cardiopulmonary outcomes relative to LAMA/LABA therapy with GFF MDI 14.4/9.6 μg in a population with COPD and elevated cardiopulmonary risk.0.77MK-8527's Phase 3 Trial in Human Immunodeficiency Virus Reads Out
ESTIMATED50% CONFIDENCEin 1.1 yearsClinicalTrials.gov[1] lists 2027-10-18 as the estimated primary completion date; a sponsor's estimate, and trials of this size routinely slip.Merck & Co.'s phase 3 trial of MK-8527 in human immunodeficiency virus reaches primary completion, the point at which the last participant's primary outcome is measured. The trial enrolled 4,580 participants. Researchers are looking for new medicines to prevent HIV-1 (Human Immunodeficiency Virus Type 1) infection. The goals of this study are to learn: * If taking MK-8527 once a month works to prevent HIV-1 infection better than a standard (usual) pre-exposure prophylaxis (PrEP) taken once a day * About the safety of MK-8527 and if people tolerate it0.73Maridebart Cafraglutide's Phase 3 Trial in Heart Failure With Preserved Ejection Fraction Reads Out
ESTIMATED50% CONFIDENCEin 1.8 yearsClinicalTrials.gov[1] lists 2028-06-30 as the estimated primary completion date; a sponsor's estimate, and trials of this size routinely slip.Amgen's phase 3 trial of Maridebart Cafraglutide in heart failure with preserved ejection fraction reaches primary completion, the point at which the last participant's primary outcome is measured. The trial enrolled 5,056 participants. This trial will examine if maridebart cafraglutide as an adjunct to standard of care will lead to a reduction in heart failure (HF) events such as HF hospitalizations and urgent HF visits, cardiovascular (CV) deaths and improvement in HF symptoms in participants with HF with preserved ejection fraction (HFpEF) and HF with mildly reduced ejection fraction (HFmrEF) who are obese. This is a phase 3, global, multicenter, 2-part trial with a double-blind period and an open-label extension (OLE). The trial is event-driven, and Part 1 will conclude when approximately 850 primary endpoint events have occurred.0.73Ibuzatrelvir's Phase 3 Trial in COVID-19 SARS-CoV-2 Infection Reads Out
ESTIMATED50% CONFIDENCEin 1.0 yearsClinicalTrials.gov[1] lists 2027-10-03 as the estimated primary completion date; a sponsor's estimate, and trials of this size routinely slip.Pfizer's phase 3 trial of Ibuzatrelvir in covid-19 sars-cov-2 infection reaches primary completion, the point at which the last participant's primary outcome is measured. The trial enrolled 2,330 participants. The purpose of the study is to evaluate whether ibuzatrelvir is effective and safe in adults and adolescents with COVID-19 who do not need to be in the hospital but who are at high risk for progression to severe disease. Eligible participants will be randomly assigned (by chance) to receive ibuzatrelvir or matching placebo orally for 5 days. Co-administration of locally available standard of care is allowed. The total duration of the study is around 6 months.0.73PG4's Phase 3 Trial in Pneumococcal Disease Reads Out
ESTIMATED50% CONFIDENCEin 2.3 yearsClinicalTrials.gov[1] lists 2028-12-30 as the estimated primary completion date; a sponsor's estimate, and trials of this size routinely slip.Pfizer's phase 3 trial of PG4 in pneumococcal disease reaches primary completion, the point at which the last participant's primary outcome is measured. The trial enrolled 2,400 participants. The purpose of this study is to learn about the safety of a new pneumococcal vaccine and how the new pneumococcal vaccine helps to fight against germs that can cause pneumonia (lung infections), meningitis (brain infections), and otitis media (ear infections) in infants when compared to the pneumococcal vaccine that is currently in use, 20vPnC (Prevnar 20®). This study will test if the new pneumococcal vaccine is as safe as the one that is currently in use. This new vaccine can possibly provide additional protection against germs that cause pneumococcal disease that are not included in the vaccines that are currently given to infants. Pneumococcal disease includes a variety of infections caused by a specific germ, Streptococcus pneumoniae. There are two groups in this study. All participants will be assigned to one of the two groups. This study is seeking participants who are: \- infants0.73Vicadrostat's Phase 3 Trial in Heart Failure Reads Out
ESTIMATED50% CONFIDENCEin 1.7 yearsClinicalTrials.gov[1] lists 2028-05-22 as the estimated primary completion date; a sponsor's estimate, and trials of this size routinely slip.Boehringer Ingelheim's phase 3 trial of Vicadrostat in heart failure reaches primary completion, the point at which the last participant's primary outcome is measured. The trial enrolled 6,000 participants. This study is open to adults aged 18 or above legal age with heart failure. People can join the study if they have heart failure symptoms and a left ventricular ejection fraction (LVEF) of 40% or more. The purpose of this study is to find out whether vicadrostat (BI 690517) in combination with empagliflozin helps people with heart failure. Participants are put into 2 groups by chance. Every participant has an equal chance of being in each group. The groups are: * Vicadrostat/empagliflozin group: participants take vicadrostat/empagliflozin as tablets once a day. * Placebo/empagliflozin group: participants take placebo/empagliflozin as tablets once a day. Participants can stay in the study as long as they benefit from treatment and can tolerate it. During this time, they visit their doctors regularly. The doctors regularly check participants' health and take note of any unwanted effects. T0.72Maridebart Cafraglutide's Phase 3 Trial in Atherosclerotic Cardiovascular Disease Reads Out
ESTIMATED50% CONFIDENCEin 1.8 yearsClinicalTrials.gov[1] lists 2028-06-30 as the estimated primary completion date; a sponsor's estimate, and trials of this size routinely slip.Amgen's phase 3 trial of Maridebart Cafraglutide in atherosclerotic cardiovascular disease reaches primary completion, the point at which the last participant's primary outcome is measured. The trial enrolled 12,800 participants. The primary objective of this trial is to demonstrate that maridebart cafraglutide is superior to placebo when given as an adjunct to standard of care with respect to reducing cardiovascular (CV) morbidity and mortality.0.72MenQuadfi's Phase 3 Trial in Meningococcal Infection Reads Out
ESTIMATED50% CONFIDENCEin 1.5 yearsClinicalTrials.gov[1] lists 2028-03-13 as the estimated primary completion date; a sponsor's estimate, and trials of this size routinely slip.Sanofi's phase 3 trial of MenQuadfi in meningococcal infection reaches primary completion, the point at which the last participant's primary outcome is measured. The trial enrolled 4,568 participants. The purpose of this study is to describe the safety and immunogenicity of MenACYW conjugate vaccine compared with locally-licensed meningococcal vaccines in healthy infants and toddlers in China. Study details include: * Study duration (including 6-month safety follow-up after the last dose): * Cohort I (Groups 1 and 2): approximately 211 or 271 days (approximately 7 or 9 months) * Cohort II (Groups 3 and 4): up to 18 months * Cohort III (Groups 5 and 6): up to 21 months * Cohort III (Group 7): approximately 16 months * Vaccination Visits Period: * Cohort I (Groups 1 and 2): a 2-dose vaccination at V01 (D01) and V02 (D31) or V03 (D91). Two blood samples are collected pre-vaccination (D01) and 30 days post the 2nd dose of vaccination (D61 or D121). Telephone calls (TCs) are planned on the 4th, the 9th, and the 21st day after each vaccination, and 5 TCs (1 TC/month) are planned for the 5 m0.72Elecoglipron's Phase 3 Trial in Type 2 Diabetes Mellitus Reads Out
ESTIMATED50% CONFIDENCEin 1.8 yearsClinicalTrials.gov[1] lists 2028-07-05 as the estimated primary completion date; a sponsor's estimate, and trials of this size routinely slip.AstraZeneca's phase 3 trial of Elecoglipron in type 2 diabetes mellitus reaches primary completion, the point at which the last participant's primary outcome is measured. The trial enrolled 2,000 participants. The purpose of this study is to evaluate the efficacy, safety, and tolerability of elecoglipron and dapagliflozin in combination, compared with elecoglipron alone and dapagliflozin alone, in adults with type 2 diabetes mellitus (T2DM) inadequately managed with lifestyle management alone or treated with other background glucose-lowering medication.0.72MRNA Seasonal Flu Vaccine's Phase 3 Trial in Influenza, Human Reads Out
ESTIMATED50% CONFIDENCEin 1.7 yearsClinicalTrials.gov[1] lists 2028-06-09 as the estimated primary completion date; a sponsor's estimate, and trials of this size routinely slip.GSK's phase 3 trial of MRNA Seasonal Flu Vaccine in influenza, human reaches primary completion, the point at which the last participant's primary outcome is measured. The trial enrolled 54,000 participants. This study will compare an investigational mRNA flu vaccine with a licensed flu vaccine in adults 65 years of age and older. Participants will receive one injection and will be followed during the flu season. The study will measure prevention of laboratory-confirmed flu illness, side effects, and immune responses.0.71Elecoglipron's Phase 3 Trial in Weight Management Reads Out
ESTIMATED50% CONFIDENCEin 1.9 yearsClinicalTrials.gov[1] lists 2028-07-31 as the estimated primary completion date; a sponsor's estimate, and trials of this size routinely slip.AstraZeneca's phase 3 trial of Elecoglipron in weight management reaches primary completion, the point at which the last participant's primary outcome is measured. The trial enrolled 4,500 participants. This master study protocol, Study D7260C00015, covers 2 independent, pivotal studies, Study 1 and Study 2. Each study is a global, randomized, double-blind, parallel-group, multicenter, Phase III study to assess the efficacy and safety of elecoglipron compared with placebo adjunct to diet and exercise for weight management, in adults living with obesity or overweight with at least one weight-related comorbidity, and without T2DM (Study 1) or with T2DM (Study 2).0.70Camizestrant's Phase 3 Trial in Breast Cancer, Early Breast Cancer Reads Out
ESTIMATED50% CONFIDENCEin 209 daysClinicalTrials.gov[1] lists 2027-04-20 as the estimated primary completion date; a sponsor's estimate, and trials of this size routinely slip.AstraZeneca's phase 3 trial of Camizestrant in breast cancer, early breast cancer reaches primary completion, the point at which the last participant's primary outcome is measured. The trial enrolled 4,300 participants. This is a Phase III open-label study to assess if camizestrant improves outcomes compared to standard endocrine therapy in patients with ER+/HER2 - early breast cancer with intermediate or high risk for disease recurrence who completed definitive locoregional therapy (with or without chemotherapy) and standard adjuvant endocrine therapy (ET) for at least 2 years and up to 5 years. The planned duration of treatment in either arm of the study is 60 months.0.70
Boehringer Ingelheim